UKAAN Conference 2019
The UK Adult ADHD Network (UKAAN) will host a one day conference on Friday 13th September 2019, preceded by a welcome reception on the evening of Thursday 12th which will start with a theatre performance of ‘Declaration’, a theatre play on ADHD, followed by food and drinks. The 1 day conference will take place at the Mermaid Conference and Events Centre in London. The venue is situated between the City and the West End, on the North Bank of the Thames, and enjoys spectacular views towards the Tate Modern, Globe Theatre and the Millennium Bridge.
This meeting will celebrate 10 years of the UK Adult ADHD network. During that time we have seen a rapid advance in our understanding of ADHD across the lifespan, the availability of diagnostic services and access to effective treatments. Advances seen in the UK are also seen in many other countries across the EU and worldwide. Overall, there has been a stepped change in the recognition of ADHD by adult mental health services, reflected in a marked increase in the numbers of adults being diagnosed and treated for ADHD. Licensed drug treatments for adult ADHD are now widely available in the UK and elsewhere for the first time, including both stimulant and non-stimulant mediations, and recommendations from guideline groups such as the National Institute of Health and Clinical Excellence (NICE). The importance of concurrent psychosocial treatments is also recognised, and mainstream psychological treatment services are also developing the understanding and skills required to manage mental health problems related to ADHD.
This meeting aims to raise the level of knowledge and expertise among health care professionals about adults with ADHD and provide a better understanding of the persistence of the disorder, the development of comorbid mental health problems and the delivery of effective treatments. The program will be delivered by prominent opinion leaders, clinical experts and internationally recognised investigators.
The meeting is designed to highlight key advances in our understanding of course and outcome; genetic, environmental, and neuroscience of ADHD; and topics relevant to the diagnosis and treatment of ADHD from adolescence to early and late adulthood. The selection of speakers is important so that the audience can hear directly from the most experienced professionals working in this rapidly developing area of clinical psychiatry.
Professor Philip Asherson